Glider | $4,000,000 | (Apr 18, 2025)
Graze Social | $1,000,000 | (Apr 18, 2025)
Nyobolt | $30,000,000 | (Apr 18, 2025)
Certified by Founder
Lodge
Curevo Vaccine
start up
United States
- Bothell, Washington
- 19/03/2025
- Series B
- $110,000,000
Curevo Vaccine is a clinical-stage developer of vaccines for varicella and herpes zoster. Amezosvatein (CRV-101) is an adjuvanted subunit (non-mRNA) vaccine designed to prevent herpes zoster, commonly known as shingles. Our goal with a new herpes zoster vaccine is to improve the patient experience and, ultimately, overall vaccination rates, by developing amezosvatein as a vaccine with non-inferior efficacy combined with clinically-meaningful improvements in reactogenicity when compared to Shingrix.
- Industry Biotechnology Research
- Website https://curevovaccine.com/
- LinkedIn https://www.linkedin.com/company/curevovaccine/
Related People
George SimeonFounder
United States -
Greater Seattle Area
Strategic Alliances, Global Commercialisation, M&A, Joint-Ventures, Organization Building
Balance between: Strategic Thinking - Creative Problem Solving - 'Hands-on' Execution
Booked it | $3,316,375 | (Apr 18, 2025)
FOTENIX | $2,785,755 | (Apr 18, 2025)
Exaforce Inc. | $75,000,000 | (Apr 18, 2025)
Pillar Security | $9,000,000 | (Apr 18, 2025)
Cy4Data Labs | $10,000,000 | (Apr 18, 2025)
Meadow | $14,000,000 | (Apr 18, 2025)
Trellis Health | $1,800,000 | (Apr 18, 2025)
RISA | $3,500,000 | (Apr 18, 2025)
Vizzy | B Corp™ | $4,841,908 | (Apr 18, 2025)
Assort Health | $26,000,000 | (Apr 18, 2025)